Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a research report sent to investors on Monday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright reduced their price target on Minerva Neurosciences from $7.00 to $5.00 and set a neutral rating for the company in a research report on Wednesday, August 7th.

Minerva Neurosciences Stock Up 1.9 %

Shares of NASDAQ:NERV opened at $2.72 on Monday. The stock has a market capitalization of $19.02 million, a PE ratio of -0.61 and a beta of 0.14. The firm’s 50 day moving average price is $2.84 and its 200-day moving average price is $2.80. Minerva Neurosciences has a twelve month low of $2.26 and a twelve month high of $13.49.

Minerva Neurosciences (NASDAQ:NERV) last released its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.12). Analysts expect that Minerva Neurosciences will post -2.26 earnings per share for the current fiscal year.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.